About PARADISE
01
PERSONALISED.
PARADISE is an ambitious research project in personalised medicine. The millions of people affected by autoimmune conditions have a reduced quality of life. Focusing on ANCA vasculitis as an exemplar relapsing multi-system autoimmune disease, PARADISE will use patient level data to identify the characteristics, or markers, most often linked to relapse events.
02
RELAPSE.
Research of this consortium already identified high-potential markers in serum, urine, transcriptomics, and autoantibodies which enabled broad grouping of patients. PARADISE will integrate these markers, delivering a truly 360°approach to relapse prediction.
03
PREDICTION.
PARADISE will train clinical decision support tools using the best available longitudinal patient data to identify associated relapse events and thus risk levels. Artificial Intelligence (AI) will be used.
04
PPI.
In PARADISE, the Public and Patient Involvement roles include: Formation of a patient focus groups (PAG = Patient Associated Group) and stakeholder groups that provide input to all patient-facing materials (consent forms, AI transparency notice, communication materials, website, patient-app user interface and documentation).
